RAF1 and colorectal carcinoma: Intuitively, given that pathway reactivation via RAF dimerization is thought to be an important mechanism limiting the efficacy of BRAF inhibitors in BRAF mutant CRC, it might be expected that the use of a paradox breaker inhibitor could provide enhanced pathway inhibition and hence enhanced efficacy.